Michael J. Fox Foundation Archives

Comic-style illustration of Michael J. Fox pointing toward Parkinson’s research and clinical trial displays, surrounded by scientists, patients and investors, with upward arrows symbolizing progress and investor optimism.

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

by John F. Heerdink, Jr. October 8, 2026 304Views 0Likes

Better biomarkers, new FDA approvals and an emerging delivery pipeline strengthen the case for Parkinson’s innovation, with AbbVie and Serina Therapeutics offering distinct investment angles. The most compelling Parkinson’s investment story does not begin with a stock chart. It begins with a…

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

by John F. Heerdink, Jr. September 25, 2026 475Views 0Likes

SER-252 enters Cohort 2 with blinded early observations that support the central premise: sustained delivery of a proven Parkinson’s medicine may be far more valuable when it asks less of patients and caregivers. In biotechnology, there are moonshots, and then there are…

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

by John F. Heerdink, Jr. September 23, 2026 186Views 0Likes

Parkinson’s disease is one of medicine’s most stubborn commercial and scientific frontiers, and Serina Therapeutics, Inc. (NYSE American: SER) is positioning its lead program, SER-252, squarely in the middle of that opportunity. The clinical-stage biotechnology company has opened registration for a Tribe Public CEO…

Tag: Michael J. Fox Foundation

The Michael J. Fox Foundation Is Building Parkinson’s Next Chapter. Investors Have Reason to Pay Attention. -( $ABBV $IBB $SER $XBI )

Serina Therapeutics Advances SER-252 in Advanced Parkinson’s Disease as Continuous Therapy Market Expands -( $ABBV $SER )

Serina Therapeutics Puts Advanced Parkinson’s Disease in the Spotlight – Thursday, September 24

Your Guide To Staying Informed In The Markets